<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440374</url>
  </required_header>
  <id_info>
    <org_study_id>114968</org_study_id>
    <secondary_id>2011-000114-19</secondary_id>
    <nct_id>NCT01440374</nct_id>
  </id_info>
  <brief_title>A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a worldwide, three-part (Part 1: open-label, Part 2: randomized, double-blind, Part
      3: extension), multi-center study to evaluate the effect of eltrombopag in subjects with
      myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who have thrombocytopenia due
      to bone marrow insufficiency from their underlying disease or prior chemotherapy. This
      objective was assessed by a composite primary endpoint that consists of the following: the
      proportion of ≥Grade 3 hemorrhagic adverse events, or platelet counts &lt;10 Gi/L, or platelet
      transfusions. Patients with MDS or AML and Grade 4 thrombocytopenia due to bone marrow
      insufficiency from their underlying disease or prior chemotherapy were enrolled in the study.
      No low or intermediate-1 risk MDS subjects were enrolled in the study. Subjects must have had
      at least one of the following during the 4 weeks prior to enrolment: platelet count &lt;10 Gi/L,
      platelet transfusion, or symptomatic hemorrhagic event. Supportive standard of care (SOC),
      including hydroxyurea, was allowed as indicated by local practice throughout the study. The
      study had 3 sequential parts. Subjects who were enrolled in Part 1 (open-label) cannot be
      enrolled in Part 2 of the study (randomized, double-blind); however, subjects who completed
      the treatment period for Part 1 or Part 2 (8 and 12 weeks, respectively) continued in Part 3
      (extension) if the investigator determined that the subject was receiving clinical benefit on
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Platelet Response up to Week 8 During Part 1</measure>
    <time_frame>From Baseline up to Week 8 during Part 1</time_frame>
    <description>A participant was considered as a responder if he/she met the following response criteria: a Baseline platelet count &lt;20 Giga cells per liter (Gi/L) and a post-Baseline increased to &gt;20 Gi/L and at least 2 times the Baseline value; or a Baseline platelet count &gt;=20 Gi/L and a post-Baseline absolute platelet count increased to &gt;=50 Gi/L and at least 2 times the Baseline value. The response criteria was evaluated at each visit. Increase in platelet count observed up to 3 days after a platelet transfusion was not considered as a platelet response. The Part 1 Population was comprised of all participants enrolled into Part 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2</measure>
    <time_frame>From Week 5 up to Week 12 during Part 2</time_frame>
    <description>A participant was considered to have a CRTE at a given assessment if he/she had platelet counts &lt;10 Gi/L, or platelet transfusions, or &gt;=Grade 3 hemorrhagic adverse events. CRTEs during Weeks 5 to 12 were compared between treatments using a generalized linear mixed model. Average of weekly proportion of subjects with CRTE during Week 5 to 12 was estimated for each treatment. Intent to Treat (ITT) Population was comprised of all randomized participants during Part 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 1 Subjects)</measure>
    <time_frame>Day 1 to week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 2 Subjects)</measure>
    <time_frame>Day 1 to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Platelet Transfusions</measure>
    <time_frame>Weeks 5 to 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Improvement</measure>
    <time_frame>Weeks 5 to 12</time_frame>
    <description>Definitions of hematologic improvement for platelets, neutrophils, and hemoglobin were based on modified International Working Group (IWG) consensus criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Platelet Count</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Duration of Platelet Transfusion Independence</measure>
    <time_frame>Weeks 5 to 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maximum Bleeding Grade According to World Health Organization on Bleeding Scale</measure>
    <time_frame>Weeks 5 to 12</time_frame>
    <description>Occurrence and severity of bleeding, measured using the WHO Bleeding Scale Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross blood loss; Grade 4=debilitating blood loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent Reviewer-Assessed Best Response</measure>
    <time_frame>up to week 12</time_frame>
    <description>Participants were evaluated in accordance with the modified International Working Group (Cheson, 2006). CR: Bone marrow blasts &lt;5%, Hgb ≥11g/dL, Hematologic Improvement - Platelets (Baseline &lt;20Gi/L: &gt;20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline), Neutrophils ≥1.0 Gi/L, Peripheral blasts 0%. PR: Bone marrow blasts decreased by ≥50% but &gt;5%, Peripheral blood as in CR. Marrow CR: Bone marrow blasts &lt;5% and decrease by ≥50%, Note any Hematologic Improvements, Stable disease: Failure to achieve PR, but no evidence of progression for &gt;8w, Cytogenetic response: Complete: disappearance of chromosomal abnormality; no new abnormalities Partial: ≥50% reduction of chromosomal abnormality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent Reviewer Assessed Disease Progression</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Health Outcomes</measure>
    <time_frame>week 12</time_frame>
    <description>The number of subject with medical resource utilization (MRU) data are reported in this table.
MRU included number of emergency room visits, number of home healthcare visits, number of hospitalization days, number of medication or surgery specialist visits, number of procedures inpatient, number of procedures outpatient, number of non-study radiology visits, number of non-study laboratory visits, number of nurse practitioner/physician assistance/nurse visits, number of primary care physician visits, number of telephone consultations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy (FACT)</measure>
    <time_frame>Change from baseline, up to week 12</time_frame>
    <description>The FACT-Th-18 is the most widely used and accepted tool evaluating health-related quality-of-life outcomes in cancer patients with chronically low platelets (where Th designates thrombocytopenia). The entire FACT-Th-18 was used in this trial, which includes the 18-item thrombocytopenia subscale used to assess the impact of symptoms, signs, and functional consequences of thrombocytopenia in MDS and AML subjects. The FACT-Th-18 is a validated and reliable instrument with known psychometric properties. FACT-ThS is an 18 item questionnaire specific to assessing the impact of symptoms, signs, and functional consequences of Thrombocytopenia. ThS score ranges from 0 to 72 with higher the score, the better the QoL. FACT G total score moves from 0 to 108 where higher the score, the better the HRQL.
FACT-Th Total Score is calculated by adding the FACT-ThS and FACT-G score. Total score ranges from 0 to 180 and again, higher the score, the better the HRQL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Utility Score Analysis</measure>
    <time_frame>Change from baseline, up to week 12</time_frame>
    <description>EuroQoL Five Dimensions Questionnaire (EQ-5D) is a standardized generic preference based health related quality of life instrument. It records how one's health is &quot;today&quot; and consists of a descriptive system. The Descriptive system is Comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life.
EQ-ED is a score.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Thrombocytopaenia</condition>
  <arm_group>
    <arm_group_label>Part 1, Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, eltrombopag arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, placebo arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>part 3 extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag</intervention_name>
    <description>100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)</description>
    <arm_group_label>part 3 extension</arm_group_label>
    <arm_group_label>Part 1, Open Label</arm_group_label>
    <arm_group_label>Part 2, eltrombopag arm</arm_group_label>
    <other_name>Promacta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)</description>
    <arm_group_label>Part 2, placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (18 years of age or older) with MDS or AML (bone marrow blasts ≤50%)
             with thrombocytopenia due to bone marrow insufficiency from the disease or prior
             treatment. Subjects with transient thrombocytopenia due to active treatment with
             disease modifying agents or chemotherapy (except for hydroxyurea) are excluded.

          -  Subjects must have Grade 4 thrombocytopenia (platelet counts &lt;25 Gi/L) due to bone
             marrow insufficiency (or Grade 4 thrombocytopenia, but platelet count greater than or
             equal to 25 Gi/L due to platelet transfusion). In addition, subjects must have had at
             least one of the following during the 4 week screening period: platelet transfusion,
             or symptomatic bleeding or platelet count &lt;10 Gi/L. Subjects whose thrombocytopenia
             below 10 Gi/L is due to causes other than bone marrow insufficiency (e.g., fever,
             infection, autoimmune disease) are not eligible.

          -  Subjects must have platelet count, bleeding and platelet transfusion data available
             over a period of at least 4 weeks prior to randomization.

          -  Prior systemic treatment for malignancy, with the exception of hydroxyurea, ﻿must have
             been discontinued prior to entry into the study: at least 4 weeks before Day 1 for the
             following: chemotherapy, demethylating agents (azacitidine or decitabine),
             lenalidomide, thalidomide, clofarabine and IL-11(oprelvekin); at least 8 weeks before
             Day 1 for antithymocyte/antilymphocyte globulin.

          -  Subjects with a prior stem cell transplant (SCT) must have relapsed after the SCT.

          -  Subjects must be stable and, in the opinion of the investigator, be expected to
             complete a 12 week treatment period.

          -  ECOG Status 0-2.

          -  Subject must be able to understand and comply with protocol requirements and
             instructions.

          -  Subject has signed and dated an informed consent form.

          -  Adequate baseline organ function defined by the criteria below: total bilirubin ≤
             1.5xULN except for Gilbert's syndrome or cases clearly not indicative of inadequate
             liver function (i.e. elevation of indirect (hemolytic) bilirubin in the absence of ALT
             abnormality), ALT ≤ 3xULN, creatinine ≤ 2.5xULN

          -  Women must be either of non-child bearing potential or women with child-bearing
             potential and men with reproductive potential must be willing to practice acceptable
             methods of birth control during the study Women of childbearing potential must have a
             negative serum or urine pregnancy test within 7 days prior to the first dose of study
             treatment.

          -  In France, a subject eligible for inclusion in this study only if either affiliated
             to, or a beneficiary of, a social security category.

        Exclusion Criteria:

          -  Subjects with MDS and an IPSS of low or intermediate-1 risk at screening.

          -  Subjects with a diagnosis of acute promyelocytic or megakaryocytic leukemia or AML
             secondary to a myeloproliferative neoplasm.

          -  History of treatment with romiplostim or other TPO-R agonists.

          -  Subjects with a QTc &gt;480 msec (QTc &gt;510 msec for subjects with Bundle Branch Block).

          -  Leukocytosis ≥25,000/uL on Day 1 of treatment with study medication.

          -  Subjects with known thrombophilic risk factors. Exception: Subjects for whom the
             potential benefits of participating in the study outweigh the potential risks of
             thromboembolic events, as determined by the investigator.

          -  Female subjects who are nursing or pregnant (positive serum or urine β-human chorionic
             gonadotropin [β-hCG] pregnancy test) at screening or pre-dose on Day 1.

          -  Current alcohol or drug abuse.

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) preceding the first dose of study medication.

          -  Active and uncontrolled infections (e.g. sepsis, hepatitis B, hepatitis C).

          -  Subjects infected with Human Immunodeficiency Virus (HIV).

          -  Subjects with liver cirrhosis (as determined by the investigator).

          -  Subjects receiving or planned to receive any prohibited medication.

          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to eltrombopag or excipient (microcrystalline cellulose, mannitol,
             polyvinylpyrrolidone, sodium starch glycolate, magnesium stearate, hypromellose,
             titanium dioxide, polyethylene glycol 400 and polysorbate 80) that contraindicates the
             subjects' participation.

          -  In France, subjects who have participated in any study using an investigational drug
             during the previous 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AXI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>C1025ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad AutÃ³noma de Buenos Aires</city>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goiânia - GO</city>
        <state>Goiás</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>GoiÃ¢nia - GO</city>
        <state>GoiÃ¡s</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>ParanÃ¡</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barretos</city>
        <state>SÃ£o Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01236030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>01236030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>128 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71201</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ioannina</city>
        <zip>45 500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chai Wan</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>KaposvÃ¡r</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>James Street</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallaght, Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tullamore</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alessandria</city>
        <state>Piemonte</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hwasun</city>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LeÃ³n</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico City</city>
        <zip>CP 14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St'Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St'Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197 089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>MÃ¡laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozuelo de AlarcÃ³n/Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pozuelo de Alarcón/Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan County</city>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Macau</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <results_first_submitted>March 10, 2016</results_first_submitted>
  <results_first_submitted_qc>May 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2016</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia (AML)</keyword>
  <keyword>acute myelogenous leukemia (AML)</keyword>
  <keyword>acute non lymphocytic leukemia (ANLL)</keyword>
  <keyword>myeloproliferative disease (MDS)</keyword>
  <keyword>myelodysplastic syndrome ( secondary acute myeloid leukemia)</keyword>
  <keyword>refractory acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Part 1, 17 subjects received open-label eltrombopag. Part 2, 145 subjects were randomized to receive eltrombopag plus SOC (N=98) or placebo plus SOC (N=47).
Part 3, 59 subjects from Part 2 entered Part 3. SOC was allowed as needed throughout the study. Subjects could receive disease-modifying therapy as needed.</recruitment_details>
      <pre_assignment_details>Participants with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) and Grade 4 thrombocytopenia due to bone marrow insufficiency and had at least one of the following: platelet count &lt;10 Giga cells per liter, platelet transfusion or symptomatic hemorrhagic event during the 4 weeks prior to enrollment, were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Eltrombopag</title>
          <description>The eltrombopag starting dose the participants received was 100 milligrams (mg) daily (50 mg for participants of East Asian heritage). The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. After all participants finished the 8 week treatment period, platelet response and safety were analyzed before initiating Part 2 of the study. Supportive standard of care was allowed as needed. The duration of Part 1 was 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Part 2: Placebo</title>
          <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Part 2: Eltrombopag</title>
          <description>The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
        </group>
        <group group_id="P4">
          <title>Part 3: Eltrombopag</title>
          <description>23 subjects of the 47 randomized to the placebo group in Part 2 entered part 3. 36 subjects of the 98 randomized to the Etrombopag group in Part 2 entered part 3.
All subjects received eltrombopag. Part 3 subjects could also have received treatment for their disease per local SOC, including azacitidine, decitabine, lenalidomide, and chemotherapy. The duration of Part 3 was to be 10 months for subjects from Part 1and 9 months for subjects from Part 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1: Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2; Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3: Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Part 3, 59 subjects from Part 2 entered Part 3 (23 of 47 subjects in the placebo group in Part 2 and 36 of 98 subjects in the eltrombopag group in Part 2). All subjects who entered Part 3 received treatment with eltrombopag. SOC was allowed as needed throughout the study. Subjects could receive disease-modifying therapy as needed.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Eltrombopag</title>
          <description>The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. After all participants finished the 8 week treatment period, platelet response and safety were analyzed before initiating Part 2 of the study. Supportive standard of care was allowed as needed. The duration of Part 1 was 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Part 2: Placebo</title>
          <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Part 2: Eltrombopag</title>
          <description>The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="98"/>
            <count group_id="B4" value="162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.5" spread="10.78"/>
                    <measurement group_id="B2" value="70.6" spread="10.72"/>
                    <measurement group_id="B3" value="72.3" spread="8.94"/>
                    <measurement group_id="B4" value="71.8" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Platelet Response up to Week 8 During Part 1</title>
        <description>A participant was considered as a responder if he/she met the following response criteria: a Baseline platelet count &lt;20 Giga cells per liter (Gi/L) and a post-Baseline increased to &gt;20 Gi/L and at least 2 times the Baseline value; or a Baseline platelet count &gt;=20 Gi/L and a post-Baseline absolute platelet count increased to &gt;=50 Gi/L and at least 2 times the Baseline value. The response criteria was evaluated at each visit. Increase in platelet count observed up to 3 days after a platelet transfusion was not considered as a platelet response. The Part 1 Population was comprised of all participants enrolled into Part 1.</description>
        <time_frame>From Baseline up to Week 8 during Part 1</time_frame>
        <population>Part 1 Population: all subjects who enrolled in Part 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Eltrombopag</title>
            <description>The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. After all participants finished the 8 week treatment period, platelet response and safety were analyzed before initiating Part 2 of the study. Supportive standard of care was allowed as needed. The duration of Part 1 was 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Platelet Response up to Week 8 During Part 1</title>
          <description>A participant was considered as a responder if he/she met the following response criteria: a Baseline platelet count &lt;20 Giga cells per liter (Gi/L) and a post-Baseline increased to &gt;20 Gi/L and at least 2 times the Baseline value; or a Baseline platelet count &gt;=20 Gi/L and a post-Baseline absolute platelet count increased to &gt;=50 Gi/L and at least 2 times the Baseline value. The response criteria was evaluated at each visit. Increase in platelet count observed up to 3 days after a platelet transfusion was not considered as a platelet response. The Part 1 Population was comprised of all participants enrolled into Part 1.</description>
          <population>Part 1 Population: all subjects who enrolled in Part 1.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2</title>
        <description>A participant was considered to have a CRTE at a given assessment if he/she had platelet counts &lt;10 Gi/L, or platelet transfusions, or &gt;=Grade 3 hemorrhagic adverse events. CRTEs during Weeks 5 to 12 were compared between treatments using a generalized linear mixed model. Average of weekly proportion of subjects with CRTE during Week 5 to 12 was estimated for each treatment. Intent to Treat (ITT) Population was comprised of all randomized participants during Part 2.</description>
        <time_frame>From Week 5 up to Week 12 during Part 2</time_frame>
        <population>Part 2 Population (Intent-To-Treat (ITT) Population: all randomized subjects in part 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Eltrombopag</title>
            <description>The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Thrombocytopenic Events (CRTE) From Week 5 up to Week 12 During Part 2</title>
          <description>A participant was considered to have a CRTE at a given assessment if he/she had platelet counts &lt;10 Gi/L, or platelet transfusions, or &gt;=Grade 3 hemorrhagic adverse events. CRTEs during Weeks 5 to 12 were compared between treatments using a generalized linear mixed model. Average of weekly proportion of subjects with CRTE during Week 5 to 12 was estimated for each treatment. Intent to Treat (ITT) Population was comprised of all randomized participants during Part 2.</description>
          <population>Part 2 Population (Intent-To-Treat (ITT) Population: all randomized subjects in part 2)</population>
          <units>percentages of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="57" upper_limit="80"/>
                    <measurement group_id="O2" value="54" lower_limit="43" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0315</p_value>
            <method>Generalized Linear Mixed Models</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.202</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.868</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 1 Subjects)</title>
        <time_frame>Day 1 to week 8</time_frame>
        <population>Pharmacokinetic population: all subjects in All Subjects Population who had a PK blood sample obtained/analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Eltrombopag</title>
            <description>The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. After all participants finished the 8 week treatment period, platelet response and safety were analyzed before initiating Part 2 of the study. Supportive standard of care was allowed as needed. The duration of Part 1 was 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 1 Subjects)</title>
          <population>Pharmacokinetic population: all subjects in All Subjects Population who had a PK blood sample obtained/analyzed.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline/day 1 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day8 week 1 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day15 week 2 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22 week 3 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 week 3 (2-6hrs post-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="14.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day36 week 5 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43 week6 (2-6hrs post-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="32.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 week 7 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="27.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day57 week 8 (2-6hrs post-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="18.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 2 Subjects)</title>
        <time_frame>Day 1 to week 12</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. After all participants finished the 8 week treatment period, platelet response and safety were analyzed before initiating Part 2 of the study. Supportive standard of care was allowed as needed. The duration of Part 1 was 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Eltrombopag Pharmacokinetic Concentration-Time Data - by Visit (Part 2 Subjects)</title>
          <population>Pharmacokinetic population</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline/day 1 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day15 week 2 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22 week 3 (2-6hrs post-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 week 4 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="13.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43 week 6 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="18.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 week 7 (2-6hrs post-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day57 week8 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day71 week 10 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day78 week 11 (2-6hrs post-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="24.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day85 week12 (Pre-dose PK)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="18.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Platelet Transfusions</title>
        <time_frame>Weeks 5 to 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Platelet Transfusions</title>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Number of platelet transfusions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="18.60"/>
                    <measurement group_id="O2" value="15.7" spread="20.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematologic Improvement</title>
        <description>Definitions of hematologic improvement for platelets, neutrophils, and hemoglobin were based on modified International Working Group (IWG) consensus criteria.</description>
        <time_frame>Weeks 5 to 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematologic Improvement</title>
          <description>Definitions of hematologic improvement for platelets, neutrophils, and hemoglobin were based on modified International Working Group (IWG) consensus criteria.</description>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets and neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets and hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, hemoglobin and neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils and hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Platelet Count</title>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Platelet Count</title>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Gi/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day8 week1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="11.795"/>
                    <measurement group_id="O2" value="1.66" spread="6.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day15 week2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.41" spread="60.225"/>
                    <measurement group_id="O2" value="3.06" spread="9.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day22 week3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.23" spread="22.872"/>
                    <measurement group_id="O2" value="2.13" spread="9.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 week4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.63" spread="17.582"/>
                    <measurement group_id="O2" value="2.44" spread="11.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day36 week5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" spread="22.504"/>
                    <measurement group_id="O2" value="5.9" spread="16.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day43 week6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.64" spread="19.779"/>
                    <measurement group_id="O2" value="5.93" spread="21.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 week7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.91" spread="25.561"/>
                    <measurement group_id="O2" value="6.74" spread="31.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day57 week8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" spread="23.243"/>
                    <measurement group_id="O2" value="7.84" spread="34.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day64 week9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="27.272"/>
                    <measurement group_id="O2" value="6.75" spread="31.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day71 week10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.97" spread="33.866"/>
                    <measurement group_id="O2" value="6.23" spread="30.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day78 week11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.42" spread="36.901"/>
                    <measurement group_id="O2" value="6.92" spread="26.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 week12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.06" spread="28.259"/>
                    <measurement group_id="O2" value="4.85" spread="26.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Duration of Platelet Transfusion Independence</title>
        <time_frame>Weeks 5 to 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Duration of Platelet Transfusion Independence</title>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>maximum duration of platelet transfusion</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="21.47"/>
                    <measurement group_id="O2" value="25.4" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maximum Bleeding Grade According to World Health Organization on Bleeding Scale</title>
        <description>Occurrence and severity of bleeding, measured using the WHO Bleeding Scale Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross blood loss; Grade 4=debilitating blood loss.</description>
        <time_frame>Weeks 5 to 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maximum Bleeding Grade According to World Health Organization on Bleeding Scale</title>
          <description>Occurrence and severity of bleeding, measured using the WHO Bleeding Scale Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross blood loss; Grade 4=debilitating blood loss.</description>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 0 (no bleeding)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (petechiae)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (mild blood loss)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (gross blood loss)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (debilitating blood loss)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grades 0 – 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grades 1 – 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grades 2 - 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Independent Reviewer-Assessed Best Response</title>
        <description>Participants were evaluated in accordance with the modified International Working Group (Cheson, 2006). CR: Bone marrow blasts &lt;5%, Hgb ≥11g/dL, Hematologic Improvement – Platelets (Baseline &lt;20Gi/L: &gt;20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline), Neutrophils ≥1.0 Gi/L, Peripheral blasts 0%. PR: Bone marrow blasts decreased by ≥50% but &gt;5%, Peripheral blood as in CR. Marrow CR: Bone marrow blasts &lt;5% and decrease by ≥50%, Note any Hematologic Improvements, Stable disease: Failure to achieve PR, but no evidence of progression for &gt;8w, Cytogenetic response: Complete: disappearance of chromosomal abnormality; no new abnormalities Partial: ≥50% reduction of chromosomal abnormality.</description>
        <time_frame>up to week 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Reviewer-Assessed Best Response</title>
          <description>Participants were evaluated in accordance with the modified International Working Group (Cheson, 2006). CR: Bone marrow blasts &lt;5%, Hgb ≥11g/dL, Hematologic Improvement – Platelets (Baseline &lt;20Gi/L: &gt;20 Gi/L and 2x baseline; Baseline ≥20 Gi/L: ≥50 Gi/L and 2x baseline), Neutrophils ≥1.0 Gi/L, Peripheral blasts 0%. PR: Bone marrow blasts decreased by ≥50% but &gt;5%, Peripheral blood as in CR. Marrow CR: Bone marrow blasts &lt;5% and decrease by ≥50%, Note any Hematologic Improvements, Stable disease: Failure to achieve PR, but no evidence of progression for &gt;8w, Cytogenetic response: Complete: disappearance of chromosomal abnormality; no new abnormalities Partial: ≥50% reduction of chromosomal abnormality.</description>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphologic CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphologic leukemia-free state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marrow CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cytogenetic CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Molecular CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease (non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease (non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable (non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Independent Reviewer Assessed Disease Progression</title>
        <time_frame>Up to week 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Reviewer Assessed Disease Progression</title>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disease progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="21.47"/>
                    <measurement group_id="O2" value="36" spread="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No disease progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <time_frame>Up to 13 months</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" lower_limit="2.96" upper_limit="7.59"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.29" upper_limit="7.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Health Outcomes</title>
        <description>The number of subject with medical resource utilization (MRU) data are reported in this table.
MRU included number of emergency room visits, number of home healthcare visits, number of hospitalization days, number of medication or surgery specialist visits, number of procedures inpatient, number of procedures outpatient, number of non-study radiology visits, number of non-study laboratory visits, number of nurse practitioner/physician assistance/nurse visits, number of primary care physician visits, number of telephone consultations.</description>
        <time_frame>week 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Health Outcomes</title>
          <description>The number of subject with medical resource utilization (MRU) data are reported in this table.
MRU included number of emergency room visits, number of home healthcare visits, number of hospitalization days, number of medication or surgery specialist visits, number of procedures inpatient, number of procedures outpatient, number of non-study radiology visits, number of non-study laboratory visits, number of nurse practitioner/physician assistance/nurse visits, number of primary care physician visits, number of telephone consultations.</description>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Subject with Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of emergency room visits (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of home healthcare visits (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of hospitalization days (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of med/surg specialist visits (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of procedures inpatient (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of procedures outpatient (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-study radiology visits (n=2, n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of nurse prac/pa/nurse visits (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of primary care physician visits (n=17,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of telephone consultations (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of non-study laboratory visits (n=17, n=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Cancer Therapy (FACT)</title>
        <description>The FACT-Th-18 is the most widely used and accepted tool evaluating health-related quality-of-life outcomes in cancer patients with chronically low platelets (where Th designates thrombocytopenia). The entire FACT-Th-18 was used in this trial, which includes the 18-item thrombocytopenia subscale used to assess the impact of symptoms, signs, and functional consequences of thrombocytopenia in MDS and AML subjects. The FACT-Th-18 is a validated and reliable instrument with known psychometric properties. FACT-ThS is an 18 item questionnaire specific to assessing the impact of symptoms, signs, and functional consequences of Thrombocytopenia. ThS score ranges from 0 to 72 with higher the score, the better the QoL. FACT G total score moves from 0 to 108 where higher the score, the better the HRQL.
FACT-Th Total Score is calculated by adding the FACT-ThS and FACT-G score. Total score ranges from 0 to 180 and again, higher the score, the better the HRQL.</description>
        <time_frame>Change from baseline, up to week 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Cancer Therapy (FACT)</title>
          <description>The FACT-Th-18 is the most widely used and accepted tool evaluating health-related quality-of-life outcomes in cancer patients with chronically low platelets (where Th designates thrombocytopenia). The entire FACT-Th-18 was used in this trial, which includes the 18-item thrombocytopenia subscale used to assess the impact of symptoms, signs, and functional consequences of thrombocytopenia in MDS and AML subjects. The FACT-Th-18 is a validated and reliable instrument with known psychometric properties. FACT-ThS is an 18 item questionnaire specific to assessing the impact of symptoms, signs, and functional consequences of Thrombocytopenia. ThS score ranges from 0 to 72 with higher the score, the better the QoL. FACT G total score moves from 0 to 108 where higher the score, the better the HRQL.
FACT-Th Total Score is calculated by adding the FACT-ThS and FACT-G score. Total score ranges from 0 to 180 and again, higher the score, the better the HRQL.</description>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Adjusted mean change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FACTG week 5 (n=61. n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="1.64"/>
                    <measurement group_id="O2" value="-3.15" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACTG week 9 (n=46. n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.83" spread="1.82"/>
                    <measurement group_id="O2" value="-2.76" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACTG week12 (n=37. n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.38" spread="1.94"/>
                    <measurement group_id="O2" value="-4.17" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACTHTOI week 5 (n=61, n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="2.04"/>
                    <measurement group_id="O2" value="-2.28" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACTHTOI week 9 (n=46, n=28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="2.24"/>
                    <measurement group_id="O2" value="0.19" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACTHTOI week 12 (n=37, n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="2.37"/>
                    <measurement group_id="O2" value="-1.56" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D Utility Score Analysis</title>
        <description>EuroQoL Five Dimensions Questionnaire (EQ-5D) is a standardized generic preference based health related quality of life instrument. It records how one’s health is “today” and consists of a descriptive system. The Descriptive system is Comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects’ health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life.
EQ-ED is a score.</description>
        <time_frame>Change from baseline, up to week 12</time_frame>
        <population>Part 2 Population (Intent-to-Treat population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Eltrombopag</title>
            <description>Part 2: Eltrombopag The eltrombopag starting dose the participants received was 100 mg daily (50 mg for participants of East Asian heritage). The duration of treatment with the initial dose level prior to first dose escalation was determined based on the platelet response and toxicity observed in Part 1. The dose of eltrombopag was escalated from 100 mg to 200 mg (50 mg to 100 mg for East Asians) and further from 200 mg to 300 mg once daily (100 mg to 150 mg for East Asians) based on the platelet response and safety data after two weeks of current dose level. Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo</title>
            <description>Participants received eltrombopag matching placebo once daily (3 tablets). Supportive standard of care was allowed as needed throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D Utility Score Analysis</title>
          <description>EuroQoL Five Dimensions Questionnaire (EQ-5D) is a standardized generic preference based health related quality of life instrument. It records how one’s health is “today” and consists of a descriptive system. The Descriptive system is Comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem(s) and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects’ health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life.
EQ-ED is a score.</description>
          <population>Part 2 Population (Intent-to-Treat population)</population>
          <units>Adjusted mean change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5 (n=55. n=34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.04"/>
                    <measurement group_id="O2" value="-0.15" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9 (n=43. n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.04"/>
                    <measurement group_id="O2" value="-0.06" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=36. n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.05"/>
                    <measurement group_id="O2" value="-0.11" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Eltrombopag, Part 1 Subjects</title>
          <description>Eltrombopag, Part 1 subjects</description>
        </group>
        <group group_id="E2">
          <title>Eltrombopag, Part 2 Plus 1 Day From Part 2 Subjects</title>
          <description>Eltrombopag, Part 2 plus 1 day from Part 2 subjects</description>
        </group>
        <group group_id="E3">
          <title>Placebo, Part 2 Plus 1 Day From Part 2 Subjects</title>
          <description>Placebo, Part 2 plus 1 day from Part 2 subjects</description>
        </group>
        <group group_id="E4">
          <title>Eltrombopag, Part 3 Plus 30 Days From Part 2 Subjects</title>
          <description>Eltrombopag, Part 3 plus 30 Days from Part 2 subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Splenic artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oral mucosal blistering</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Viral oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Body temperature fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Serum ferritin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

